NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 58 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $153,135 | -6.6% | 184,500 | -21.2% | 0.00% | – |
Q1 2023 | $163,940 | +28.7% | 234,200 | -6.4% | 0.00% | – |
Q4 2022 | $127,403 | -49.4% | 250,300 | -36.5% | 0.00% | -100.0% |
Q3 2022 | $252,000 | -36.8% | 394,000 | +1.7% | 0.00% | 0.0% |
Q2 2022 | $399,000 | -26.5% | 387,600 | +34.1% | 0.00% | 0.0% |
Q1 2022 | $543,000 | -52.0% | 289,000 | +23.1% | 0.00% | -66.7% |
Q4 2021 | $1,131,000 | -10.4% | 234,700 | +34.4% | 0.00% | 0.0% |
Q3 2021 | $1,262,000 | +129.0% | 174,600 | +192.5% | 0.00% | +200.0% |
Q2 2021 | $551,000 | -44.2% | 59,700 | -25.7% | 0.00% | -66.7% |
Q1 2021 | $988,000 | -47.4% | 80,300 | -39.7% | 0.00% | -40.0% |
Q4 2020 | $1,877,000 | +96.3% | 133,100 | +67.0% | 0.01% | +66.7% |
Q3 2020 | $956,000 | +48.9% | 79,700 | +105.9% | 0.00% | +50.0% |
Q2 2020 | $642,000 | +184.1% | 38,700 | +94.5% | 0.00% | +100.0% |
Q1 2020 | $226,000 | -31.5% | 19,900 | -25.7% | 0.00% | 0.0% |
Q4 2019 | $330,000 | +202.8% | 26,800 | -30.2% | 0.00% | – |
Q3 2019 | $109,000 | – | 38,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |